A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis

(2013) Karoline Kollmann et al.   CANCER CELL

Cyclin-dependent kinase inhibitors closer to market launch?

(2013) Hervé Galons et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

Cell Cycle-Based Therapies Move Forward

(2012) Marcos Malumbres   CANCER CELL

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors

(2011) D. Mahadevan et al.   ANNALS OF ONCOLOGY

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

(2010) Neil Johnson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions

(2010) Sopee Poomsawat et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

(2010) Matthew S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

(2010) L Santo et al.   ONCOGENE

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

(2009) M. S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†

(2008) Paul G. Wyatt et al.   JOURNAL OF MEDICINAL CHEMISTRY